ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

Wender Named ACS Chief Cancer Control Officer

August 9, 2013

NCAB, Panel May Look A Discrepancies, In Study Section Evaluation Of Grant Applications

September 4, 1981

Approval Granted For New Formulation of Lupron Depot

July 29, 2011

In Brief: Satcher Names CDC Director; POG Appoints Monaco To Data Monitoring Committee

September 10, 1993

University of Pittsburgh Cancer Institute Wins Core Grant Renewal

October 1, 2010

Breast Cancer Coalition to Congress: ‘Find a Way To Fund The War,’ Bypass Level Is Not Enough

August 7, 1992